" class="no-js "lang="en-US"> Emalex Announces First Patient Dosed in Tourette Syndrome Trial
Sunday, September 24, 2023

Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome

Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of Tourette Syndrome.

Participants in the trial receive ecopipam for 12 weeks in the open-label phase of the study. Those with at least a 25% reduction in the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) at both week 8 and 12 will be randomized to continue on ecopipam or placebo in the double-blind phase of the study until they relapse, up to an additional 12 weeks. Efficacy will be assessed as the difference in time-to-relapse between groups.

“Tourette Syndrome is a serious condition for which there is significant unmet need,” said Amanda Talty, Tourette Association of America president and CEO. “Currently, the two classes of medicines commonly used to treat Tourette can have a number of concerning side effects. We are happy to see the progress of additional studies being conducted to test new treatment alternatives for our community.”

Emalex closed an upsized and oversubscribed $250 million Series D round led by Bain Capital Life Sciences in November to fund the Phase 3 trial and potential commercialization of ecopipam. The trial is expected to enroll more than 200 patients across 90 sites in North America and Europe.

Ecopipam is a first-in-class dopamine-1 receptor antagonist. The antipsychotic agents currently approved to treat Tourette syndrome target the dopamine-2 receptor and are associated with serious side effects. Patients enrolled in the Phase 2b D1AMOND study did not have observable evidence of adverse movements, excessive weight gain, or the metabolic side effects commonly reported with antipsychotic agents. The most frequent ecopipam-related adverse events in the study were headache (9.2%), fatigue (6.6%), somnolence (6.6%), insomnia (5.3%), and restlessness (5.3%).

Tourette Syndrome is a chronic, childhood-onset neurodevelopmental disorder characterized by motor and vocal tics. The condition is associated with both increased mortality and significant morbidity. In the majority of individuals, Tourette Syndrome substantially impacts day-to-day physical and social function. Principal investigator Donald Gilbert, MD, a movement disorders specialist at the Cincinnati Children’s Hospital, noted patients’ tics often cause pain and injury in addition to social stigma and emotional distress.

“My patients have an urgent need for safer and more effective treatments. Tourette interferes with daily activities and commonly has negative impacts on mental and emotional health. For children and teens, Tourette can affect school performance and social development, which has lifelong consequences,” Dr. Gilbert said.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more